Inclusion Body Myositis Market
Report ID: SQMIG20I2830
Report ID: SQMIG20I2830
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG20I2830 |
Region:
Global |
Published Date: April, 2026
Pages:
157
|Tables:
118
|Figures:
77
Global Inclusion Body Myositis Market size was valued at USD 542.5 Million in 2024 and is poised to grow from USD 570.17 Million in 2025 to USD 544.9 Million by 2033, growing at a CAGR of 5.1% during the forecast period (2026-2033).
The primary driver of the inclusion body myositis market is the growing recognition and diagnosis of the disease, which has transformed a previously neglected neuromuscular field into a targeted therapeutic opportunity substantially. Inclusion body myositis is a progressive inflammatory myopathy that predominantly affects older adults and leads to muscle weakness and loss of function, so the market matters because unmet medical need and aging populations create sustained demand for treatments that can alter disease trajectory. Over the past decade improved diagnostic criteria, biomarker discovery, and imaging advances have raised case ascertainment and redirected academic and industry resources toward translational programs and repurposing efforts substantially.A central growth factor in the global inclusion body myositis market is progress in clinical development and regulatory engagement, because successful late-stage trials increase commercial prospects and attract strategic partnerships. As candidate therapies demonstrate functional or biomarker improvement, investors provide capital, which accelerates manufacturing scale-up and global distribution planning. Improved patient registries and digital recruitment reduce trial timelines, thereby lowering cost per approval and making niche indications commercially viable. In practice this produces opportunities for companion diagnostics, rehabilitation devices, and adjunctive care models, exemplified by expanded physiotherapy programs and specialized care centers that translate trial outcomes into measurable patient benefit.
How is AI accelerating drug discovery and patient stratification in the inclusion body myositis market?
AI speeds drug discovery in inclusion body myositis by compressing cycles from hypothesis to candidate selection. Machine learning uncovers novel targets and suggests engineered proteins so teams can prioritize biologics that match disease biology. AI also extracts meaningful patterns from clinical notes imaging and biomarker data to define patient subgroups and risk profiles. That makes trials more efficient by identifying patients who are more likely to respond and by refining endpoints. Given the rarity and unmet need in this market, these approaches complement traditional research and help translate emerging pipeline activity into more focused development efforts.Abcuro February 2026, reported topline results from its ulviprubart trial which highlighted a subgroup signal, and AI driven patient stratification tools can help replicate that insight by identifying who is likely to benefit earlier, improving trial efficiency and guiding next steps for development.
Market snapshot - (2026-2033)
Global Market Size
USD 542.5 Million
Largest Segment
Immunosuppressant & Corticosteroids
Fastest Growth
Gene Therapies & Myostatin Inhibitors
Growth Rate
5.1% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global inclusion body myositis market is segmented by therapeutic approach, supportive care & management, diagnostic interface, end-user and region. Based on therapeutic approach, the market is segmented into Immunosuppressant & Corticosteroids, Targeted Monoclonal Antibodies (Biologics), Protein Homeostasis Modulators and Gene Therapies & Myostatin Inhibitors. Based on supportive care & management, the market is segmented into Physical & Occupational Therapy Equipment, Orthotic Devices & Mobility Aids and Speech & Swallowing Therapy Services. Based on diagnostic interface, the market is segmented into Electromyography (EMG) & Nerve Conduction, Muscle Biopsy & Histopathology and MRI & Antibody Testing (Anti-cN1A). Based on end-user, the market is segmented into Neuromuscular Specialty Centers, Rehabilitation Clinics and Academic & Clinical Research Hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Targeted Monoclonal Antibodies (Biologics) segment leads because it directly addresses immune-mediated pathology in inclusion body myositis with mechanism specific interventions that can modulate pathogenic pathways while limiting systemic toxicity associated with broad immunosuppression. Clinical signals and mechanistic rationale have attracted investment and specialized trial design, which drives clinician adoption and formulary interest, concentrates development expertise in biologics manufacturing, and catalyzes a pipeline focus that reinforces its market prominence.
However, Gene Therapies & Myostatin Inhibitors are the fastest growing area because they focus on muscle restoration and durable functional improvement, drawing translational research and regulatory interest; this momentum drives trial activity, investment in delivery platforms and biomarkers, and creates new commercial pathways that expand future treatment opportunities.
Muscle Biopsy & Histopathology segment dominates because it remains the diagnostic reference standard for inclusion body myositis, providing definitive histologic evidence of rimmed vacuoles, inflammatory infiltrates and protein inclusions that clarify complex differentials and inform eligibility for clinical trials. Its ability to guide personalized management and to validate emerging biomarkers concentrates specialist pathology services, supports diagnostic confidence for clinicians, and sustains demand for integrated diagnostic workflows.
Conversely, MRI & Antibody Testing (Anti-cN1A) is experiencing the strongest growth as noninvasive imaging and biomarker assays enable earlier detection, patient stratification, and longitudinal monitoring; expanding clinical adoption and standardization efforts enhance diagnostic throughput, support less invasive enrollment for trials, and drive commercial demand for combined imaging and serologic diagnostic solutions.
To get detailed segments analysis, Request a Free Sample Report
North America dominance stems from an integrated ecosystem that supports rapid diagnosis, therapy development, and market access for complex neuromuscular conditions. A dense network of academic medical centers and specialized clinics enables early identification and coordinated care, while a vibrant biotechnology and pharmaceutical sector drives innovation and commercialization. Mature clinical trial infrastructure and active patient advocacy accelerate research translation, and clear regulatory and reimbursement pathways facilitate uptake of novel therapies. Strong public and private investment, together with collaborative partnerships among industry, clinicians, and patient groups, sustain a pipeline of clinical development and ensure that therapeutic advances progress from research settings to clinical practice across the region.
Inclusion Body Myositis Market in United States is characterized by concentrated research capabilities, extensive clinical trial networks, and a strong presence of biotech and pharmaceutical innovators. High levels of clinical expertise and specialized neuromuscular centers support rapid diagnostic adoption and complex care pathways. Robust collaboration between commercial developers, academic institutions, and patient organizations facilitates product development and market access, ensuring therapeutic advances reach clinical practice and broaden access to care.
Inclusion Body Myositis Market in Canada benefits from a coordinated healthcare framework, strong funding for rare disease initiatives, and collaborative research networks focused on neuromuscular disorders. Specialized clinics and integrated referral pathways enable diagnosis and multidisciplinary management. Close cooperation between academic centres, provincial health authorities, and patient organizations advances clinical trial participation and adoption of new care models, helping translate research discoveries into improved patient support and therapeutic options nationwide.
Europe expansion is propelled by a confluence of robust clinical expertise, collaborative research networks, and increasingly harmonized regulatory and reimbursement environments that support rare disease innovation. Established neuromuscular centers across major markets enable earlier diagnosis and integrated care, while pan-European consortia and patient registries facilitate multi-country clinical development and knowledge sharing. Strong engagement from regional pharmaceutical and biotech firms, combined with active academic partnerships, drives localized research and commercialization efforts. Policy focus on rare disease pathways and improved awareness among clinicians and payers accelerates access to novel diagnostics and therapies. Cross-border collaboration leverages complementary national strengths, positioning Europe as a rapidly advancing region for inclusion body myositis treatment development and patient care.
Inclusion Body Myositis Market in Germany is driven by a strong clinical research ecosystem, advanced hospital networks, and concentrated expertise in neuromuscular diseases. Established centers of excellence support complex diagnostics and integrated care pathways, while close industry collaboration accelerates clinical development. Reimbursement clarity and patient advocacy contribute to adoption of novel therapies. Coordinated efforts among academia, industry, and healthcare providers underpin Germany role as a leading market in the region.
Inclusion Body Myositis Market in United Kingdom benefits from concentrated clinical research, strong academic leadership, and innovative trial approaches that accelerate evaluation of therapies. Use of national health data and coordinated registries improves patient identification and evidence generation. Collaboration between research hospitals, regulatory authorities, and patient groups supports streamlined development and pragmatic adoption of new care models, strengthening United Kingdom position as a high growth market for inclusion body myositis.
Inclusion Body Myositis Market in France is emerging due to investment in rare disease networks, expanding specialist clinics, and improved diagnostic capabilities. National research programs and collaborative hospital networks enhance patient referral and multidisciplinary care. Growing engagement from domestic biotech firms and academic centers supports clinical research, while patient organizations contribute to awareness and recruitment. These developments position France as an increasingly important market for inclusion body myositis interventions nationally.
Asia Pacific is strengthening its role through strategic investments in clinical capacity, research capabilities, and regulatory modernization that together foster a more competitive environment for inclusion body myositis development and uptake. Markets such as Japan and South Korea exhibit concentrated clinical expertise and growing numbers of specialized treatment centers, supporting improved diagnosis and multidisciplinary management. Domestic biotechnology and pharmaceutical firms are increasingly active and often partner with global developers to localize trials and adapt therapies to regional needs. Regulatory authorities are enhancing pathways for orphan and specialty products, while payers and health systems are gradually aligning mechanisms to support access, advancing regional readiness to contribute to global innovation in care.
Inclusion Body Myositis Market in Japan benefits from advanced healthcare infrastructure, concentrated clinical expertise, and active domestic biotech engagement. Specialized neuromuscular centers and diagnostic laboratories support comprehensive patient pathways and clinical assessment. Supportive regulatory and payer frameworks, combined with collaborative research consortia, encourage local development and clinical testing. Partnerships among industry, academic institutions, and patient groups facilitate study enrollment and help translate research into routine clinical practice nationwide across regions.
Inclusion Body Myositis Market in South Korea is supported by a technologically advanced healthcare system, efficient hospital networks, and an active clinical research community. Adoption of diagnostics and therapies is enabled by collaboration between biopharma and academic centres, supported by constructive regulatory engagement. Focus on digital health and data integration improves patient identification and care coordination. Industry, hospitals, and patient groups collaborate to increase trial activity and clinical adoption nationally.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Advances In Diagnostic Technologies
Growing Therapeutic Research Activity
High Development Costs
Limited Disease Awareness
Request Free Customization of this report to help us to meet your business objectives.
Competitive landscape for inclusion body myositis is shifting as big pharmas and nimble biotechs pursue differentiated modalities, driving partnerships, acquisitions, and platform licensing. Examples include AbbVie's acquisition of Mitokinin to access mitophagy programs and argenx advancing efgartigimod into myositis Phase 2 and 3. These moves incentivize startups to secure grants or strategic deals and accelerate technology innovation for muscle targeted therapeutics.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, growing recognition and improved diagnostic technologies are a key driver for the inclusion body myositis market, expanding diagnosed patient pools and enabling targeted trials. A restraint is high development costs that limit program diversity and slow candidate progression. North America is the dominating region due to concentrated research centers, strong industry presence and clear access pathways, while Targeted Monoclonal Antibodies is the dominating segment driven by mechanism-specific biologics attracting investment. A second driver is accelerated clinical development and regulatory engagement, which together with AI-enabled patient stratification shortens trial timelines and increases commercial viability for niche therapeutics.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 542.5 Million |
| Market size value in 2033 | USD 544.9 Million |
| Growth Rate | 5.1% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Inclusion Body Myositis Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Inclusion Body Myositis Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Inclusion Body Myositis Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Inclusion Body Myositis Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
